Literature DB >> 8313932

An overview of glucocorticoid anti-inflammatory actions.

R P Schleimer1.   

Abstract

Glucocorticoids (GC) exert a variety of important anti-inflammatory actions. We have studied their effects in allergic inflammation and believe that their anti-allergic effects reflect their anti-inflammatory activities in general. These effects include inhibition of cytokine and other mediator secretion, inhibition of leucocyte priming in eosinophils and neutrophils, reduction of vascular permeability, inhibition of arachidonic acid metabolite and platelet activating factor (PAF) release, synergistic or permissive effects on responses to other mediators, such as catecholamines and other endogenous hormone-like molecules, and modulation of enzyme systems involved in inflammation. Glucocorticoid actions are thus multifaceted; this feature explains both their unequalled efficacy in inflammatory diseases and the difficulty in replacing them with other medications that have a uni-dimensional profile of action.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8313932     DOI: 10.1007/bf01844196

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  34 in total

1.  Inhibition of in vitro lymphokine synthesis by glucocorticosteroids.

Authors:  S M Wahl; L C Altman; D L Rosenstreich
Journal:  J Immunol       Date:  1975-08       Impact factor: 5.422

2.  Modulation of human polymorphonuclear leukocyte IgG Fc receptors and Fc receptor-mediated functions by IFN-gamma and glucocorticoids.

Authors:  K C Petroni; L Shen; P M Guyre
Journal:  J Immunol       Date:  1988-05-15       Impact factor: 5.422

3.  Glucocorticoids inhibit neurogenic plasma extravasation and prevent virus-potentiated extravasation in the rat trachea.

Authors:  G Piedimonte; D M McDonald; J A Nadel
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

4.  Expression of endothelial-leukocyte adhesion molecule-1 in elicited late phase allergic reactions.

Authors:  D Y Leung; J S Pober; R S Cotran
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

5.  Production of granulocyte-macrophage colony-stimulating factor by cultured human tracheal epithelial cells.

Authors:  L Churchill; B Friedman; R P Schleimer; D Proud
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

6.  Glucocorticoids inhibit cytokine-mediated eosinophil survival.

Authors:  N Wallen; H Kita; D Weiler; G J Gleich
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

7.  Inhibition of human basophil leukotriene release by antiinflammatory steroids.

Authors:  R P Schleimer; D A Davidson; S P Peters; L M Lichtenstein
Journal:  Int Arch Allergy Appl Immunol       Date:  1985

8.  Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells.

Authors:  R P Schleimer; E S Schulman; D W MacGlashan; S P Peters; E C Hayes; G K Adams; L M Lichtenstein; N F Adkinson
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

9.  Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

Authors:  B Beutler; N Krochin; I W Milsark; C Luedke; A Cerami
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

Review 10.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

View more
  35 in total

Review 1.  Sepsis-induced immunosuppression: from bad to worse.

Authors:  R C Reddy; G H Chen; P K Tekchandani; T J Standiford
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Effects of high-dose corticosteroids on post-traumatic inflammatory mediators.

Authors:  Olav Reikerås; Arthur Helle; Claus Danckert Krohn; Jens Ivar Brox
Journal:  Inflamm Res       Date:  2009-06-28       Impact factor: 4.575

3.  Expression and function of MIP-2 are reduced by dexamethasone treatment in vivo.

Authors:  R Schramm; Q Liu; H Thorlacius
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

4.  Characterization of a novel anti-inflammatory factor produced by RM3/1 macrophages derived from glucocorticoid treated human monocytes.

Authors:  W Hamann; A Flöter; W Schmutzler; G Zwadlo-Klarwasser
Journal:  Inflamm Res       Date:  1995-12       Impact factor: 4.575

5.  Pregnenolone-16alpha-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms.

Authors:  Carylyn J Marek; Steven J Tucker; Dimitrios K Konstantinou; Lucy J Elrick; Dee Haefner; Charalambos Sigalas; Graeme I Murray; Bryan Goodwin; Matthew C Wright
Journal:  Biochem J       Date:  2005-05-01       Impact factor: 3.857

6.  Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.

Authors:  D M Hammerbeck; S M McGurran; P L Radziszewski; E A Egging; D D Johnson; A M Hupperts; G W Gullikson
Journal:  Inflammation       Date:  2000-08       Impact factor: 4.092

Review 7.  From stress to inflammation and major depressive disorder: a social signal transduction theory of depression.

Authors:  George M Slavich; Michael R Irwin
Journal:  Psychol Bull       Date:  2014-01-13       Impact factor: 17.737

Review 8.  Gastroprotective action of glucocorticoid hormones during NSAID treatment.

Authors:  L P Filaretova; T T Podvigina; T R Bagaeva; A Tanaka; K Takeuchi
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

9.  Fetuin (alpha2-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules.

Authors:  H Wang; M Zhang; M Bianchi; B Sherry; A Sama; K J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

10.  Contrast-enhanced power Doppler sonography of knee synovitis in rheumatoid arthritis: assessment of therapeutic response.

Authors:  F Salaffi; M Carotti; P Manganelli; E Filippucci; G M Giuseppetti; W Grassi
Journal:  Clin Rheumatol       Date:  2004-05-15       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.